From the perspective of driving the creation of new businesses for Society 5.0, a supply of long-term, large-scale risk capital is required for business fields that can be globally competitive, such as biotechnology, drug discovery, and healthcare. But the life science field has several challenges, including the small number of growth-stage startups, insufficient growth among startups that reach this stage, and poorly designed capital policies.
Against this backdrop, VGF2 targets startups with the potential to capture a significant market (First in Class or Best in Class) or that have a technological competitive advantage, providing support for business growth and capital policy up to exit. VGF2 focuses on the life science field, offering comprehensive support from the early to middle stages (in the case of drug discovery, from submission of clinical trial notification to the start of clinical trials) and exit strategy to eliminate gaps between investment stages and create next-generation industries. The fund promotes business growth through hands-on support, including assistance for global business development and overseas listing.
*For early-stage investments, the fund intends to address the shortage of risk capital in the life science sector, and assumes that investments will be made together with other VCs who will act as lead VC (including cases in which the fund is co-lead VC).
